For the second time ever, a pig heart has been transplanted into a living human recipient.
The groundbreaking surgery was done at the University of Maryland Medical Center by the same transplant team that preformed the first such experimental surgery in 2022. This most recent transplant occurred on September 20. In a news release, the hospital said the recipient, 58-year-old Lawrence Faucette, “is currently breathing on his own, and his heart is functioning well without any assistance from supportive devices.”
Faucette had end-stage heart disease and was deemed ineligible for a traditional transplant with a human heart by the University of Maryland team as well as other transplant teams due to pre-existing peripheral vascular disease and complications with internal bleeding, said UMMC in a press release.
“My only real hope left is to go with the pig heart, the xenotransplant,” Faucette told the hospital in an internal interview several days before the surgery.
The experimental xenotransplant surgery was green lit under the US Food and Drug Administration’s “compassionate use” program. According to the FDA, the program is “a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.”
The pig heart used came from a genetically modified pig from the United Therapeutics Corporation. The pig is modified to eliminate the alpha gal sugar in the pig’s blood cells, which can trigger a severe reaction in the human immune system, causing organ rejection. The FDA first approved the gene edited pigs in 2020.
Doctors are also treating Faucette with an experimental antibody treatment to further suppress the immune system and prevent rejection. He will be closely monitored for any signs of rejection or any development of pig related viruses. The donor pig was also closely screened for any signs of virus or pathogens.
“We are once again offering a dying patient a shot at a longer life, and we are incredibly grateful to Mr. Faucette for his bravery and willingness to help advance our knowledge of this field,” said Dr. Bartley Griffith, in the release. Griffith is the surgeon who performed the transplant and is a professor of surgery at the University of Maryland.
The hospital said Faucette fully consented to the experimental treatment and was informed of all the risks. In addition, he underwent a full psychiatric evaluation and discussed his case with a medical ethicist.
According to the hospital’s news release, Faucette is a married father of two from Frederick, Maryland and a 20-year Navy veteran who had most recently worked as a lab technician at the National Institutes of Health before retiring.
“We have no expectations other than hoping for more time together,” said his wife Ann Faucette, in the release. “That could be as simple as sitting on the front porch and having coffee together.”
There are currently no clinical trials that utilize pig organs for transplants in living human beings. The University of Maryland performed the first such experimental surgery on 57-year-old David Bennett in January 2022. Bennett died two months following the surgery.